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Abstract: Low-protein diets (LPDs) are often considered as contraindicated in diabetic patients, and
are seldom studied. The aim of this observational study was to provide new data on this issue.
It involved 149 diabetic and 300 non-diabetic patients who followed a LPD, with a personalized
approach aimed at moderate protein restriction (0.6 g/day). Survival analysis was performed
according to Kaplan–Meier, and multivariate analysis with Cox model. Diabetic versus non-diabetic
patients were of similar age (median 70 years) and creatinine levels at the start of the diet (2.78 mg/dL
vs. 2.80 mg/dL). There was higher prevalence of nephrotic proteinuria in diabetic patients (27.52% vs.
13.67%, p = 0.002) as well as comorbidity (median Charlson index 8 vs. 6 p = 0.002). Patient survival
was lower in diabetic patients, but differences levelled off considering only cases with Charlson
index > 7, the only relevant covariate in Cox analysis. Dialysis-free survival was superimposable
in the setting of good compliance (Mitch formula: 0.47 g/kg/day in both groups): about 50%
of the cases remained dialysis-free 2 years after the first finding of e-GFR (estimated glomerular
filtration rate) < 15 mL/min, and 1 year after reaching e-GFR < 10 mL/min. In patients with type 2
diabetes, higher proteinuria was associated with mortality and initiation of dialysis. In conclusion,
moderately restricted LPDs allow similar results in diabetic and non non-diabetic patients with
similar comorbidity.
Keywords: chronic kidney disease; low-protein diets; diabetes; diabetic nephropathy; patient
survival; dialysis start
1. Introduction
Diabetic nephropathy is a complex condition with varying clinical manifestations and responses
to therapy. The classic term “diabetic nephropathy” points to the presence of a single, well defined,
and identifiable kidney disease, characterized by a sequence of phases from increased glomerular
Nutrients 2016, 8, 649; doi:10.3390/nu8100649 www.mdpi.com/journal/nutrients
Nutrients 2016, 8, 649 2 of 17
filtration rate (GFR), micro-albuminuria, proteinuria and hypertension, to reduced GFR with increasing
proteinuria [1]. This pattern, clearly identified in type 1 diabetic patients, does not precisely describe
the situation of a growing cohort of type 2 diabetic patients, mainly characterized by scarce proteinuria
and diffuse vascular disease. In these patients the distinction between “diabetic nephropathy” and
“diabetes as comorbidity” where diabetes is “just” a part of a dysmetabolic syndrome, may not be
easy [2–8]. Hence, the term “diabetic kidney disease” is sometimes preferred in order to identify the
whole cohort of diabetic patients with chronic kidney disease (CKD) [9]. Several studies have tried
to highlight the differences between diabetes as a primary cause of CKD and diabetes as a comorbid
condition, leading to conflicting data. This is also on account of the definition of diabetic nephropathy,
based upon proteinuria, diabetes duration, retinopathy or, more rarely, kidney biopsy [10–13].
Diabetic patients represent the prototype of “frail patients” on dialysis; as a whole they are still
increasing in number [14–19], and are often central to the bioethical issues on end-of-life and on the
boundaries between excessive care and palliative treatments [20–23]. As in all fragile patients, delaying
or avoiding starting dialysis is perceived to be a primary goal [24,25].
Low protein diets are increasingly being reconsidered for their potential to retard progression
or to delay starting dialysis; however, the literature on diabetic patients is relatively scant [26,27].
Diabetic subjects are seldom included in randomised controlled trials (RCTs) on low-protein diets
and, in the face of limited evidence, a nihilist attitude often prevails due to of the expectation of a
modest effect, low compliance and risk of malnutrition, furthermore complicating already complex
therapies [28].
The few studies on low protein diets (LPDs) in diabetic patients in the new millennium, may
however suggest reconsidering this attitude, in younger as well as in older patients [29–32].
The present study is aimed at discussing this issue of diet, diabetes and start of dialysis from
a different angle, from a setting in which moderately restricted low-protein diets are systematically
offered to all patients.
Are “our present” diabetic patients on LPDs different, with regard to disease progression,
compliance, and mortality, from non-diabetic patients with similar age and comorbidity scores?
With this aim, we compared the results obtained in 149 diabetic patients with a homogeneously
treated cohort of 300 non-diabetic patients, followed-up in the same setting, in the period 2007–2015.
2. Experimental Section
2.1. Study Setting, Patient Selection and Inclusion Criteria
The study was carried out at the Outpatient Nephrology Unit of the San Luigi Hospital, University
of Torino, Italy, in the period from 1 December 2007 to 31 March 2015. All subjects with at least one
month of follow-up on LPD were included in the present study.
In the study setting, LPD is routinely proposed by the nephrologist to all patients with CKD
stages IV–V who are not on dialysis, and to those with rapid progression of CKD stage III and/or
with refractory nephrotic syndrome, in the absence of contraindications, as described elsewhere in
detail [33,34]. CKD was defined according to the Kidney Disease Outcome Quality Initiative (K/DOQI)
clinical practice guidelines, and stages were defined as per the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) equation [6,35]. Diabetic nephropathy was defined either by the kidney
biopsy, or, in its absence, on clinical grounds (in the presence of retinal disease, long lasting diabetes
and proteinuria). In all other cases, in which a different diagnosis was available or suspected, diabetes
was considered as comorbid condition. Type 1 and type 2 diabetes was defined by the reference
diabetologist; five patients with steroid-induced diabetes were analyzed together with the type 2
diabetes subset.
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2.2. Diets and Controls
Italy is a setting in which the management of low protein diets is still a part of the expertise
of the nephrologist. Consequently, the diets were originally designed and prescribed by a trained
nephrologist, following the need to simplify follow-up, and a dietician was involved in specific cases
(patients who were overweight or underweight, or with nutritional intolerances) [36–38]. A dedicated
dietician joined the team in the last 3 years, allowing a further improvement in personalisation of
the treatments.
Over time, the LPD options changed from two main moderately restricted LPDs (vegan,
supplemented with ketoacids, or based on protein-free food, both free of charge in Italy), to multiple
diet options, described more in detail elsewhere [33,34,37,38]. The main characteristics of the diets
are reported in Table 1. Overall, the diets share a qualitative and flexible approach; three of them are
merely qualitative: those based upon the substitution of normal starches with protein-free commercial
food, the vegan supplemented diets and the vegan non-supplemented diets, which require a constant
integration among different plant-based food. Two are qualitative and quantitative: the “traditional
diets”, that are based upon a quantitative approach mainly resulting in a Mediterranean-style diet,
and very low protein diets, which are employed in a minority of the cases, and are based upon a
combination of a vegan supplemented diet and the use of protein free starches (Table 1).
Table 1. The main diet strategies.
Qualitative Strategies
0.6 g/Kg/day with
Protein-Free Food 0.6 g/Kg/day Vegan Supplemented
0.6–0.8 g/Kg/day Vegan
not Supplemented
The strategy is to replace bread and
pasta or rice, and regular flour with
protein-free products.
No restriction regards vegetables;
fruits may be limited in
diabetic patients.
Food of animal origin, including
dairy products, can be used as
“seasoning” for the pasta, or as part
of the “main course” that has to be
completed with vegetables.
The diet is based on plant-derived
food (fruit, vegetables, sugars,
starches such as pasta and bread,
cous-cous, polenta and legumes)
supplemented by a mixture of
amino acids and ketoacids.
Supplements allow choosing any
preferred plant-derived food
without needing to integrate grains
and legumes at each meals.
The supplements are calculated as
1 tablet per 8–10 kg of body weight,
the difference depending on
proteinuria and nutritional status.
The diet is strictly vegan and
includes only foods of plant origin
(fruit, vegetables, starches,
legumes); they must be combined
to allow a balanced intake of
essential amino acids.
In order to integrate the proteins,
the role of thumb is to integrate
during the day at least two sources
of starches with two kinds of
legumes, or at least one type of
starch and legume at each meal.
Other strategies, qualitative and quantitative: 0.6 g/Kg/day non-supplemented or 0.3 g/Kg/day
vegan supplemented
Traditional 0.6 diets are employed in patients who prefer to keep a wide variety of food in the diet, and weigh
them. Such a diet is usually designed with the dietician and is based upon a series of “equivalences” in protein
portions. At least 40% of the proteins should be of animal origin.
Vegan supplemented very low-protein diet (0.3 g/kg/day): This is a combination of vegan supplemented and
protein-free food: starches are substituted with protein-free food and supplement doses are doubled (1 for each
5 kg of BW). The quantity of legumes may have to be restricted to adhere to the 0.3 target.
Wine and beer are allowed in moderate quantities. Natural fruit juices are allowed, taking care to avoid
sweeteners, taste enhancers and preservatives. Other commercial beverages (sodas) should be avoided.
1–3 unrestricted meals per week are allowed: i.e., without any qualitative or quantitative restrictions, unless
required for other diseases (diabetes, celiac disease, food intolerances etc.).
Qualitative and quantitative modifications may be suggested according to the results of the blood and
urinary controls.
NOTE: (modified from Reference [38]).
The dietary protein intake was calculated as for real weight except for patients with body mass
index (BMI) over 30, for which we normalised the intake at a BMI of 30. Mitch formula was calculated
as per real body weight.
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To protect from malnutrition and to facilitate compliance, 1–3 unrestricted meals per week
(i.e., without any quantitative or qualitative restriction) were allowed; the number of unrestricted meals
depends on the patients’ preferences and on the kidney function, being usually, but not necessarily,
limited to 1–2 in the case of stage 5 CKD [37–39].
Daily energy intake was aimed at 30–35 kcal/kg/day per real weight if below 30 of BMI, and
individualized above it; caloric intake was calculated on the basis of a diet journal. In stable patients,
protein intake was calculated by the Maroni-Mitch formula 2–4 times per year [40]. Adjustments of
the diet were made, if needed, at each clinical visit, controlling weight, laboratory parameters and
overall well-being; sodium was not routinely reduced, but the control on 24 h urine collection of
sodium, phosphate and urea (Mitch formula) allowed continuous adjustment of dietary counselling.
Bioimpedence was performed on demand. The other aspects of care followed the current best practices
for CKD patients.
2.3. Collected Data
Comorbidities were assessed according to the Charlson index [41].
Biochemical parameters were assessed in the patient’s laboratory of choice (for about 70% the
General Laboratory of our hospital). For the sake of uniformity in the dosage methods, only the results
of tests performed in the General Laboratory of the hospital were included in the analysis of metabolic
balance and compliance and, due to several changes in laboratory methods, the analysis was focussed
on prevalent patients at the completed follow-up (31 March 2015).
2.4. Statistical Analysis
A descriptive analysis was performed as appropriate (median and range for non-parametric
data, mean and standard deviation for parametric distribution), data are presented as proportions
for dichotomous variable and as median and range for continuous ones. Statistical significance
of differences between proportions was tested through Chi square or Fisher test. For multiple
comparisons, ANOVA was performed.
For time-dependent variables, survival analysis was performed according to Kaplan–Meier also in
order to identify the relevant covariates to be entered into a multivariate analysis. Statistical difference
in survival curves was tested through Log-rank test, which is a Mantel–Haenzsel statistic applied to
survival data, as it supplies a valid test for the null hypothesis that the incidence rates for the exposed
and non-exposed group are equal between strata.
Two main outcomes were considered: dialysis (time to dialysis, or renal death), and mortality.
The beginning of the observation was the start of the diet (or, for seven patients already on the diet
in another centre, the referral to the Unit). The end of the period of observation was the end of the
diet. For survival, in a separate analysis we considered also a period including the first year after
discontinuation of the diet or dialysis start, to control for a negative carry-over effect of the diet.
A separate analysis was performed starting with the observation at the first recording of GFR < 10
or < 15 mL/min, considered as toughly equivalent to a policy of “late” and “early” start of dialysis.
Cox analysis (mortality and renal replacement therapy-RRT start) was performed adjusting for
the following covariates: Charlson index (dichotomized at 7); presence or absence of diabetes; GFR
(dichotomized at 30 mL/min) and proteinuria (dichotomized at 1 g/day) at the start of the diet. Age,
which is included in the Charlson index, was not entered in the model due to co-linearity. Wald test
was used to test the global null hypothesis (beta = 0) [42].
2.5. Ethical Issues
Informed consent was obtained for anonymous management of the clinical data.
The observational study design (PROTEREne: PROTEin REduction to protect the renal function)
was based on standard clinical practice to include patients with severe CKD, and was approved by
the Ethics Committee of the San Luigi Hospital, University of Torino (Delibera 22, 18 January 2013,
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protocol 000037). The database was built as a work in progress, being continuously updated, and
data collection will be closed in December 2016 (as for dialysis start and mortality). The data are
available upon request from the corresponding author, and will be deposited in a data depository after
completion of the final updating.
3. Results
3.1. Baseline Data
The main baseline characteristics of the study population are reported in Tables 2–4, for diabetic
patients and non-diabetic patients.
Table 2. Baseline Characteristics of the diabetic and non-diabetic Chronic Kidney Disease (CKD)
populations studied.
Diabetic Patients Non-Diabetic Patients p (Diab-Non-Diab)
N
149 300 -
(33.18%) (66.82%)
Males (%)
87 190
0.315(58.39%) (63.33%)
BMI 27.14 25.71
0.07median (min–max) (15.5–44.92) (13.32–46.67)
IQR 4.8 4.79
Age 70 70
0.467median (min–max) (19–92) (23–97)
IQR 13 22.5
Age over 65 (%) 78 118 0.006(52.35%) (39.33%)
Age over 80 (%) 23 66 0.141(15.44%) (22.00%)
Charlson 8 6
0.002median (min–max) (2–13) (2–13)
IQR 3 4
Charlson≥ 7 (%) 122 124 <0.001(81.88%) (41.33%)
Charlson≥ 10 (%) 44 27 <0.001(29.53%) (9.00%)
Cardiopathy (%) 63 145 0.171(42.28%) (48.33%)
sCreatinine (mg/dL) 2.78 2.8
0.436median (min–max) (0.90–6.80) (0.55–16)
IQR 1.47 1.88
eGFR-EPI (mL/min) 20 20
0.797median (min–max) (6.3–79.7) (3–127.10)
IQR 11.2 15.9
GFR < 15 mL/min at
enrolment n (%)
35 90
0.147(23.49%) (30.00%)
GFR < 10 mL/min at
enrolment n (%)
13 31
0.589(8.72%) (10.33%)
Proteinuria (g/day) 0.8 0.7
0.553median (min–max) (0.08–15.80) (0.04–11)
IQR 2.95 1.7
Proteinuria≥ 1 g/day (%) 78 124 0.027(52.35%) (41.33%)
Proteinuria≥ 3 g/day (%) 41 41 0.002(27.52%) (13.67%)
Legend: Charlson: Charlson’s comorbidity index; E-GFR EPI: Glomerular Filtration Rate (GFR) according to the
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation: Diab: Diabetes; IQR: Interquartile
range; BMI: Body Mass Index.
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Table 3. Baseline characteristics of the diabetic CKD population, according to the diets chosen.
Diabetic Patients Vegan Suppl. With Protein-FreeFood Other All Cases
p among
Groups
N (%)
59 70 20 149 -
(39.60%) (46.98%) (13.43%) (100%)
Males (%)
40 39 8 87
0.076(67.80%) (55.71%) 40% (58.39%)
BMI 27.11 27.26 27.15 27.14
0.95median (min–max) (18.49–42.03) (17.45–44.92) (20.31–36.32) (15.5–44.92)
IQR 4.07 4.89 7.65 4.8
Age 68 73 65 70
<0.001median (min–max) (19–85) (50–92) (29–85) (19–92)
IQR 11 10 19.5 13
Age over 65 (%) 28 44 6 78 0.013(47.46%) (62.86%) (30%) (52.35%)
Age over 80 (%) 4 16 3 23 0.001(6.78%) (22.86%) (15%) (15.44%)
Charlson 8 9 8.5 8
0.022median (min–max) (2–11) (5–13) (2–12) (2–13)
IQR 2 2 5.5 3
Charlson≥ 7 (%) 45 63 14 122 0.043(76.27%) (90%) (70%) (81.88%)
Charlson≥ 10 (%) 10 27 7 44 0.023(16.95%) (38.57%) (35%) (29.53%)
Cardiopathy (%) 28 28 7 63 0.54(47.46%) (40%) (35%) (42.28%)
SCreatinine (mg/dL) 2.9 2.7 2.5 2.78
0.761median (min–max) (0.90–6.80) (1–6.40) (1.15–4.90) (0.90–6.80)
IQR 1.7 1.3 1.75 1.47
eGFR-EPI (mL/min) 20.4 19.85 18.9 20
0.214median (min–max) (6.30–79.70) (7.70–61) (8.80–67.80) (6.3–79.7)
IQR 19.3 9.1 10.8 11.2
GFR < 15 mL/min at
enrolment n (%)
16 15 4 35
0.693(27.12%) (21.43%) (20%) (23.49%)
GFR < 10 mL/min at
enrollment n (%)
7 5 1 13
0.522(11.86%) (7.14%) (5%) (8.72%)
Proteinuria (g/day) 1.6 0.5 1.4 0.8
0.017Median (min–max) (0.10–10) (0.08–15.80) (0.20–10.40) (0.04–15.80)
IQR 4.1 1.8 2.8 2.95
Proteinuria≥ 1 g/day
(%)
40 27 11 78
0.004(67.80%) (38.57%) (55%) (52.35%)
Proteinuria≥ 3 g/day
(%)
23 13 5 41
0.001(38.98%) (18.57%) (25%) (27.52%)
Legend: Charlson: Charlson’s comorbidity index; E-GFR EPI: GFR according to the CKD-EPI equation;
Vegan suppl.: Vegan supplemented diet; IQR: Interquartile range.
In the context of moderate protein restriction, different patients choose different diets, and older
patients, in both subsets, tend to choose the “simplest diets” with protein-free food, while younger
patients often prefer vegan supplemented diets. A minority of the cases, often with intermediate
clinical features, chooses other personalized options.
In both subsets (Table 2), the median age was high, and the median Charlson index was at or
above 7, a level considered for identifying “high comorbidity”. While the BMI is widely scattered,
the mean value (27, in diabetic as well as in non-diabetic patients) identifies a slightly overweight
population (Table 2).
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Table 4. Baseline characteristics of the non-diabetic CKD population, according to the diets chosen.
Non Diabetics Vegan Suppl. With Protein-FreeFood Other All Cases
p among
Groups
N (%) 156 (52%) 89 (29.67%) 55 (18.33%) 300 (100%) -
Males (%) 104 (66.67%) 59 (66.29%) 27 (49.09%) 190 (63.33%) 0.053
BMI 25.72 26.3 24.87 25.71
0.08median (min–max) (13.32–41.03) (17.96–42.52) (17.81–46.67) (13.32–46.67)
IQR 4.74 5.24 5.5 4.79
Age 63 78 72 70
<0.001median (min–max) (23−86) (26–97) (23−88) (23–97)
IQR 25 12 22 22.5
Age over 65 (%) 58 38 22 118 0.692(37.18%) (42.70%) (40%) (39.33%)
Age over 80 (%) 16 27 13 66 0.001(10.26%) (30.13%) (23.64%) (22%)
Charlson 5 7 6 6
<0.001median (min–max) (2–12) (2–13) (2–11) (2–13)
IQR 4 2 4 4
Charlson≥ 7 (%) 46 55 23 124 <0.001(29.48%) (61.80%) (41.81%) (41.33%)
Charlson≥ 10 (%) 7 15 5 27 0.005(4.49%) (16.85%) (9.09%) (9%)
Cardiopathy (%) 73 39 33 145 0.144(46.80%) (43.82%) (60%) (48.33%)
SCreatinine (mg/dL) 3.2 2.4 2.49 2.8
<0.001median (min–max) (0.55–16) (1.05–7) (0.60–6.70) (0.55–16)
IQR 2.5 1.3 1.38 1.88
eGFR-EPI (mL/min) 17.15 21.4 24.3 20
0.367median (min–max) (3–125.70) (6.60–73.10) (5.70–127.1) (3–127.10)
IQR 14.2 13.8 17.8 15.9
GFR < 15 mL/min at
enrolment n (%)
64 17 9 90
0.001(41.02%) (19.10%) (16.36%) (30%)
GFR < 10 mL/min at
enrolment n (%)
22 5 4 31
0.107(14.10%) (5.62%) (7.28%) (10.33%)
Proteinuria (g/day) 1 0.2 0.8 0.7
<0.001Median (min–max) (0.10–8.20) (0.04–6.10) (0.10–11) (0.04–11)
IQR 2.1 0.45 1.8 1.7
Proteinuria≥ 1 g/day
(%) 85 (54.49%) 15 (16.85%) 24 (43.64%) 124 (41.33%) 0.001
Proteinuria≥ 3 g/day
(%) 27 (7.31%) 6 (6.74%) 8 (14.55%) 41 (13.67%) 0.096
Legend: Charlson: Charlson’s comorbidity index; E-GFR EPI: GFR according to the CKD-EPI equation;
Vegan suppl.: Vegan supplemented diet; IQR: Interquartile range.
Serum creatinine and GFR are in line with the usual indications to the start of a low-protein diet.
The presence of a quota of patients who start the diet at or below 10–15 mL/min of GFR (8%–30% in
the various subsets) shows a policy of offering a LPD trial also as a rescue treatment to retard dialysis
(Tables 2–4). In line with the population starting dialysis in Europe, the prevalence of type 2 diabetes
in advanced CKD patients outnumbers type 1 diabetes by over 10:1. While all patients with type 1
diabetes were clinically diagnosed as having diabetic nephropathy, only about one third of the patients
with type 2 diabetes were considered to have “true diabetic nephropathy” on clinical grounds (Table 5).
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Table 5. Diabetic patients divided according to type of diabetes and diabetes as comorbid factor or kidney disease.
Diabetic Patients Type 1 Type 2 p Type 2 CKD Type 2Comorb p
Type 2
PtU ≥ 1 g
Type 2
PtU < 1 g p
149 12 137 42 95 - 70 67 -
Males (%)
4 83
0.076
26 57
0.833
47 36
0.109(33.33%) (60.58%) (61.90%) (60%) (67.10%) (53.70%)
BMI 23.24 27.39
0.014
27.97 27.18
0.17
27.55 26.99
0.84median (min–max) (18.49–29.32) (18.33–44.92) (18.77–41.03) (20.37–44.92) (19.15–41.03) (20.37–44.92)
IQR 4.98 4.61 6.28 3.99 4.57 4.37
Age 43.5 71
0.031
66.5 72
0.181
68 73
0median (min–max) (29–62) (19–92) (46–85) (19–92) (47–86) (19–92)
IQR 15.5 12 10 11 11 13
Age over 65 (%) 0 119 (86.86%) - 31 (73.81%) 88 (92.63%) 0.001 46 (65.70%) 61 (91%) 0
Age over 80 (%) 0 40 (29.20%) - 6 (14.28%) 34 (35.79%) 0.011 5 (7.1%) 18 (26.90%) 0.002
Charlson 4 9
0.06
8 9
0.032
8 9
0.035median (min–max) (2–8) (2–13) (5–11) (2–13) (5–11) (2–13)
IQR 1.5 3 2 2 2 2
Charlson≥ 7 (%) 2 (16.17%) 120 (87.59%) 0 33 (78.57%) 87 (91.58%) 0.033 58 (82.90%) 62 (92.50%) 0.071
Charlson≥ 10 (%) 0 (0%) 44 (32.12%) 0.019 6 (14.29%) 38 (40%) 0.0002 14 (20.29%) 30 (44.12%) 0.003
Cardiopathy (%) 3 (25%) 93 (67.88%) 0.009 25 (59.52%) 68 (71.58%) 0.163 41 (58.60%) 52 (77.60%) 0.013
SCreatinine 2.45 2.8
0.393
2.6 2.9
0.858
2.89 2.7
0.695median (min–max) (0.9–4.7) (1–6.8) (1–6.4) (1.1–6.8) (1–6.8) (1.4–5)
mg/dL IQR 1.95 1.4 1.5 1.4 1.6 2.4
eGFR-EPI (mL/min) 24.95 19.8
0.026
20.85 19.5
0.993
19.3 19.9
0.875median (min–max) (12.10–79.70) (6.3–75.5) (6.3071.60) (7.4–77.7) (6.3–75.5) (7.7–54.5)
IQR 21.3 10.7 14.1 11.2 11.5 10.1
GFR < 15 at start n (%) 3 (25%) 32 (23.36%) 0.897 8 (19.05%) 24 (25.26%) 0.428 16 (22.90%) 16 (23.90%) 0.524
GFR < 10 at start n (%) 0 13 (9.49%) 0.264 5 (11.90%) 8 (8.42%) 0.472 10 (14.30%) 3 (4.5%) 0.05
PtU (g/day) 3.05 1
0.041
3.25 0.5
0
3 0.25
0median (min–max) (0.2–10.4) (0.1–15.8) (0.2–15.8) (0.08–7) (1–15.8) (0.1–0.9)
IQR 4.1 2.67 3.5 1.3 3.2 0.3
Legend: Charlson: Charlson’s comorbidity index; E-GFR EPI: GFR according to the CKD-EPI 587 equation; CKD: Chronic kidney disease; comorb: Comorbidity; PtU: Proteinuria; IQR:
Interquartile range. Type 2: Five patients with steroid-induced diabetes are included.
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Since proteinuria is central, even if not a condition sine qua non, to the definition of diabetic
nephropathy, patients were also stratified according to proteinuria, dichotomized at 1 gram (Table 5).
3.1.1. Main Outcomes: Patient Survival
The overall follow-up on diet averaged 2 years in all the considered subsets (tables a, b on line).
The multiple-choice, tailored LPD approach was probably the main reason why the incidence of
discontinuation or loss to follow-up was very low and not different in the two groups (overall eight
patients, 2%). As expected by the high comorbidity index, death was the main cause of discontinuation
in the diabetes group (52 patients, 34.9%). Fifty deaths were recorded in the non-diabetes group; in
both the main causes of death were cardiovascular and infectious.
Of note, no patient died due to refusal to start dialysis or within a palliative care pathway.
Survival rates, which were obviously different in the overall diabetic and non-diabetic populations,
are levelled off in populations with comparable comorbidity (Charlson index at or above 7) (Figure 1).
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Figure 1. Patient survival in diabetic and non-diabetic CKD patients: All cases and patients with
Charlson index ≥ 7.
Survival is significantly affected by Charlson ndex, but neither the presence of diabetes,
nor kidney function or proteinuria at baseline retain a significant effect on mortality in Cox analysis
(Table 6).
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Table 6. Crude and adjusted hazard ratios of mortality and renal replacement therapy start, by diabetes,
Charlson index, proteinuria, and GFR (Cox analysis).
MORTALITY
n/N Crude RR(95% CIs) p Value
Adjusted HR
(95% CIs) p Value
Diabetes 52/149 1.4534
<0.0001
1.146
0.5173No-Diabetes 51/300 (1.1831–1.7855) (0.758–1.733)
Charlson index
<0.0001 <0.0001<7 14/203 4.0188 5.155
≥7 89/246 (2.4465–6.6014) (2.851–9.320)
Proteinuria (g/day)
<0.0001 0.0615<1 74/247 0.6959 0.654
≥1 29/202 (0.5928–0.8170) (0.419–1.021)
GFR (mL/m)
0.1065 0.0928<30 85/344 0.9071 0.644
≥30 18/105 (0.8144–1.0104) (0.385–1.076)
RRT START
n/N Crude RR(95% CIs) p Value
Adjusted HR
(95% CIs) p Value
Diabetes 32/149 0.9658
0.6584
0.781
0.3175No-diabetes 70/300 (0.8303–1.1234) (0.481–1.268)
Charlson index
0.0138 0.1098<7 57/246 0.7529 0.692
≥7 45/203 (0.6090–0.9308) (0.441–1.087)
Proteinuria (g/day)
<0.0001 <0.0001<1 34/247 1.8415 3.703
≥1 68/202 (1.3823–2.4533) (2.409–5.691)
GFR (mL/m)
<0.0001 <0.0001<30 96/344 0.7594 0.115
≥30 6/105 (0.6994–0.8245) (0.005–0.267)
Legend: GFR: Glomerular filtration rate (EPI formula); RR: Relative risk; HR: Hazard ratio. RRT: Renal
replacement therapy.
3.1.2. Main Outcomes: Dialysis Start
The time to renal replacement therapy curve is shown in Figure 2 for diabetic and non-diabetic
patients. Once more, the differences, already non-significant in the overall population, disappear or
level off in similar populations (Charlson index above 7) (Figure 2).
Similarly, no significant difference was found in non-diabetic and in diabetic populations with
low GFR (Figure 3).
Figure 3 reports the time to RRT since the first finding of GFR at or below 15 mL/min and
10 mL/min. Of note, half of the patients are still not dialysis dependent 2 years after the first finding
of a GFR below 15 mL/min (about one case out of four is still dialysis independent after 4 years)
and 1 year after GFR < 10 mL/min, once more without significant differences due to the presence
of diabetes.
Cox analysis, performed for both outcomes of death and RRT start, confirms the importance of
proteinuria or low GFR in reaching the outcome of dialysis start, which is not modified by the presence
of diabetes or by Charlson index (Table 6).
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4. Diabetes as CKD or Diabetes as Comorbidity
The definitions of “diabetic nephropathy” and of “proteinuric CKD diabetic patients” identify a
younger subset of the diabetic population, with lower comorbidity and higher prevalence of severely
reduced kidney function (Table 5). As a reflection of these differences, patient survival was lower in the
older scarcely proteinuric cohort. The time to RRT was shorter in patients with diabetic nephropathy or
proteinuria at start of the diet over 1 g/day. The differences are once more levelled off if only patients
with Charlson index at or above 7 are considered.
5. Compliance and Metabolic Balance
Table 7 reports the main biochemical data in a subset of 168 patients, on a 0.6 g/kg/day diet, who
underwent metabolic and renal functional assessment in the general laboratory of our hospital before
31 March 2015. This subset does not differ from the overall on-diet population (225 patients) as of
March 2015 in terms of age, comorbidity index and other clinical parameters. This presumably reflects
only the patient choice in terms of reference laboratory.
Table 7. Compliance and main biochemical data at the last update: 168 on-diet patients who underwent
biochemical profiling before 31 March 2015 (at the San Luigi General Laboratory).
Patients Diabetes No Diabetes p Diab Non-Diab
N 168 41 127 -
sCreatinine mg/dL 2.89 2.67
0.587median (min–max) (1.27–4.93) (1.20–9)
IQR 3.33 1.7
Proteinuria g/day 0.73 0.8
0.924median (min–max) (0.02–11) (0–7.9)
IQR 1.94 1.79
s-albumin g/dL 3.72 3.8
0.627median (min–max) (1.8–4.7) (2.39–5.7)
IQR 0.7 0.6
Albumin < 3 g/dL n (%) 9 (21.95%) 12 (9.45%) 0.021
PTH pg/mL 114 94.9
0.014Median (min–max) (41–734) (8–848)
IQR 88.95 94.4
Urea mg/dL 96 90
0.335median (min–max) (37–232) (19–280)
IQR 63 61
HCO3 mEq/dL 26.1 25.1
0.891median (min–max) (17.7–39) (14.3–34)
IQR 5.35 4.4
Protein intake (Mitch formula) g/kg/day 0.47 0.47
0.894median (min–max) (0.27–0.76) (0.21–0.86)
IQR 0.21 0.17
Hb1ac (%) 7.2
Median (min–max) (4.5–9.8)
IQR 11.5
Legend: IQR: Interquartile range; PTH: Parathyroid hormone.
In the context of a similar estimated glomerular filtration rate (e-GFR), there was overall good
control of acidosis and of parathyroid hormone (PTH), even within a very wide range. Diet compliance
was very good, without differences between diabetic and non-diabetic patients.
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Table 8. Table on line only. Main outcomes: Distribution according to the presence, absence of diabetes.
Diabetes No Diabetes
p
Diabetes vs. Diabetes
n (Overall: 449) 149 (33.18%) 300 (66.82%) -
Continues n (%) 59 (39.60%) 166 (55.33%) 0.002
Discontinued n (%) 3 (2.01%) 5 (1.66%) 0.793
Transferred n (%) 0 (0%) 6 (2%) 0.082
Lost To Follow-up n (%) 3 (2.01%) 2 (0.66%) 0.200
On Dialysis n (%) 32 (21.48%) 70 (23.33%) 0.658
Dead n (%) 52 (34.90%) 51 (17%) 0.001
Mean Follow-up (Months) Mean± SD 25.80 ± 21.04 21.35 ± 20.41 0.321
6. Discussion
This is probably the only recent large observational study comparing diabetic and non-diabetic
patients on moderately restricted low protein diets. In the context of the present wide definition of
“diabetic kidney”, our study demonstrated that the results in diabetic patients do not differ significantly
from those recorded in populations with similar age and comorbidity patterns (Table 6; Figures 1–3).
This observation, is derived from a diabetic CKD population made up of about 90% type 2
diabetes patients, in which diabetes is more often observed in the context of vascular disease and
metabolic syndrome, and is not in keeping with recent observations suggesting that diabetic patients
have different CKD progression as compared to non-diabetic patients, or different response to the
diet [43,44]. To the contrary, our study suggests that, at least in the last CKD stages, and under the
effect of a moderately restricted low-protein diet, the risk of death and of progressing to dialysis is
comparable to that of non-diabetic subjects, once adjusting for comorbidity (Table 6, Figures 1 and 2).
However, with respect to the study by Young and co-workers, our patients were mainly
Caucasians, had lower BMI and were recruited in stages 4–5 of CKD. Furthermore, the early referral
policy of diabetic patients has been a goal in our region in the new millennium, thus probably leading
to a good overall metabolic control of the patients we follow in our settings, which was probably not
the case in the larger African-American studies [43,45].
Unlike the recent meta-analysis by Rughooputh, our data were not obtained in the context of RCTs,
but in a multiple-choice diet system in which patients were free to choose their own diet, and over 40%
of them were on supplemented moderately restricted LPDs (supplemented diets were excluded from
the meta-analysis). Another point is that only four of the studies included in the meta-analysis were
published in the same period in which our study was carried out, thus suggesting that heterogeneity
of the period of follow-up may have affected the results [43,46–49].
The dependence of the results upon the design of the meta-analysis, as for the effect of the diet is
obvious. While the classic Cochrane review did not suggest an effect of LPDs on CKD progression,
both the older study from Pedrini and the newer one from Nezu (including more cases in early CKD
stages) suggest that, on the contrary, LPDs may have a favourable effect, in accordance with what was
observed in non-diabetic patients [50–52].
Furthermore, our data is in contrary to the view that low compliance impairs the results of LPDs
in diabetic patients. In our experience, compliance to a moderately restricted LPD was identical
in diabetic and non-diabetic patients, and was in fact very good, with an observed protein intake
even slightly below target (Table 7). This last observation has to be contextualized in the system of
prescriptions and controls. In our diet, 1–3 unrestricted meals are allowed every week, with the aim
of improving compliance and protecting against malnutrition. Patients are instructed to perform the
blood and urinary tests at least 48 after an unrestricted meal [33,34,38,39]. Furthermore, Mitch formula
does not consider the fecal losses, and thus is considered to slightly underestimate the protein intake.
Since we were concerned about malnutrition, in both groups the protein intake was calculated on
real weight, while the population is overall moderately overweight (BMI 27, Table 2). In any case,
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acknowledging the risks of malnutrition, the finding of a drop in protein intake is always taken as an
indication to increase the intake, or change the strategy.
The data are in line with previous studies from our group, reporting a protein intake between
0.5 and 0.65 g/kg/day; the difference with the previous studies is essentially linked to the recent
standardization of the urinary collection distanced from an unrestricted meal [33,34].
Taken together, our results support a wider use of a moderate protein restriction in diabetic
patients, and suggest that the flexible, multiple-choice approach may allow finding a suitable diet, with
low discontinuation rates and a good compliance, also in elderly, diabetic high comorbidity patients
(Tables 1–3 and Table 6).
While our study design was not aimed at assessing the effect of LPDs on CKD progression,
the efficacy in terms of safely delaying dialysis start is indirectly shown by the years of observation
recorded since the first time e-GFR dropped to, or below, 15 mL/min, equivalent to “early dialysis
start”, or 10 mL/min, equivalent to “late-conventional dialysis start” (Figure 3).
These data gain value when contextualized with previous data from our group which found
mortality rates of patients on dialysis-free follow-up to be equal to, or lower than, the most important
dialysis registry world-wide i.e., the United States Renal Data System (USRDS) [33]. Standardized
mortality rates provide an indicative estimate of the relative risk for death in populations of different
sizes. This was about 0.5 compared with the Italian data and about 0.3 compared with USRDS, and
did not change considering or not the first period of follow-up after start of dialysis, to control for a
negative carry-over effect of LPDs.
Like all clinical studies, ours has both merits and limitations. It includes one of the largest
recently available cohorts of diabetic patients treated with a moderately restricted low-protein
diet, in comparison with a non-diabetic CKD population with similar clinical features and
homogeneous follow-up.
Furthermore, data on compliance were available for only 75% of the cohort on treatment as
of March 2015, and are not fully comparable with previous data as for distance from unrestricted
meals [33,34]. The design of the study was not tailored to nutritional safety; such a question would
have required a more sophisticated design, with standardized measurements at fixed intervals, and
the involvement, from the start, of an expert dietician.
The promising results, together with the limitations of our study, highlight the need for a
prospective multicentric analysis aimed at assessing in greater detail the advantages and drawbacks of
moderately restricted low-protein diets in different cohorts of diabetic patients.
7. Conclusions
The results we obtained in a multiple-choice diet system, targeted at a moderate protein restriction,
suggest that diabetic CKD patients should be offered the option of LPDs with moderate protein
restriction in order to retard the need for dialysis.
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